NASDAQ: ONCBeone Medicines Ltd Stock
$269.63-6.90 (-2.5%)
Updated Jun 13, 2025
ONC Price
$269.63
Fair Value Price
N/A
Market Cap
$29.13B
52 Week Low
$141.31
52 Week High
$287.88
P/E
-929.76x
P/B
8.33x
P/S
6.97x
PEG
N/A
Dividend Yield
N/A
Revenue
$4.18B
Earnings
-$392.37M
Gross Margin
84.8%
Operating Margin
-7.33%
Profit Margin
-9.4%
Debt to Equity
0.67
Operating Cash Flow
$212M
Beta
0.95
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
ONC Overview
BeOne Medicines, formerly known as BeiGene, is a global oncology company focused on discovering, developing, and commercializing innovative cancer therapies. Founded in 2010 and headquartered in Cambridge, Massachusetts—with operations spanning over 45 countries across six continents—the company rebranded as BeOne in late 2024 and redomiciled to Basel, Switzerland in 2025. BeOne has established itself as a leader in immuno-oncology and targeted therapies, with key assets including Tevimbra (tislelizumab), a PD-1 monoclonal antibody approved for multiple cancer indications globally, and Brukinsa (zanubrutinib), a Bruton's tyrosine kinase (BTK) inhibitor that surpassed $1.3 billion in annual sales and is approved in major markets such as the U.S., Europe, and China. The company’s strategy combines internal R&D with the development of assets sourced from external partnerships, driving a robust pipeline across hematologic malignancies and solid tumors.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine ONC's potential to beat the market
BBuy
- Stocks with a Zen Rating of Buy (B) had an average return of +19.88% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
ONC
Ranked#17 of 464
Ranked#17 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $8.18 | A | |
| $41.59 | A | |
| $23.53 | A |
Be the first to know about important ONC news, forecast changes, insider trades & much more!
ONC News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how ONC scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
ONC is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
ONC is poor value based on its book value relative to its share price (8.33x), compared to the US Biotechnology industry average (4.66x)
P/B vs Industry Valuation
ONC is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more ONC due diligence checks available for Premium users.
Valuation
ONC price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-929.76x
Industry
-108.97x
Market
31.36x
ONC price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
8.33x
Industry
4.66x
ONC is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
ONC's financial health
Profit margin
Revenue
$1.1B
Net Income
$1.3M
Profit Margin
0.1%
ONC's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
ONC's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$5.8B
Liabilities
$2.3B
Debt to equity
0.67
ONC's short-term assets ($3.90B) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
ONC's short-term assets ($3.90B) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
ONC's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
ONC's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$44.1M
Investing
-$121.9M
Financing
-$33.8M
ONC's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
ONC vs Biotech Stocks
Beone Medicines Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.